METABOLEX , PHASE 2 TRIAL OF MBX-802, Study Will Assess Drug’s Benefit, Alone and with Lipitor®, in Overweight or Obese Patients

September 25, 2007 - Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced that it has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides to assess the drug’s effect on dyslipidemia, insulin-resistance and obesity... Metabolex's Press release -